The company’s strategy is to focus on the development of oncology products by immatics alone or in collaboration with strong partners from the life science industry.

In-licensing: immatics seeks in-licensing opportunities for pre-clinical and clinical substances complementing existing activities of the company in the field of active immunotherapy for oncology.

Out-licensing: it is an integral component of the business model of immatics to capitalize on the value proposition of the immatics discovery engine and the short time required for transition of new product candidates from discovery to pre-clinical and clinical testing.

To learn more about partnering opportunities with immatics, please contact:

immatics biotechnologies GmbH
- Business Development Group -
Fraunhoferstraße 18b
82152 Martinsried/Planegg
Germany
 

Dr. Rainer Kramer
Phone: +49/89/540415-0
Fax: +49/89/540415-905

-/ Meet BD:

April 6-10, 2013
-/ AACR, Washington DC

-/ Presenting: Harpreet Singh/CSO
-/ www.aacr.org

April 22-25, 2013
-/ BIO International, Chicago

-/ www.convention.bio.org

May 14-16, 2013
-/ CIMT, Mainz, Germany

-/ www.meeting.cimt.eu

May 21-22, 2013
-/ Sachs Cancer Bio Partnering, Boston

-/ www.sachsforum.com

May 31-June 4, 2013

-/ ASCO, Chicago

-/ www.asco.org

June 19-21, 2013
-/ The BioPharmaceutical Conference, Divonne Les Bains, France
-/ www.biopharmaconference.com

Sept 27-Oct 1, 2013
-/ ESMO, Amsterdam
-/ www.esmo.org

Nov 4-6, 2013
-/ BioEurope, Vienna
-/ www.ebdgroup.com/bioeurope

Nov 8-10, 2013
-/ SITC 28th Annual Meeting, Wahington, DC
-/ www.sitcancer.org